BridgeBio Pharma (BBIO) Key Ratios

$76.77

up-down-arrow $2.74 (3.69%)

As on 04-Nov-2026 13:39EST

Market cap

info icon

$14,600 Mln

Revenue (TTM)

info icon

$946 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

123.7

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 44.93 192.60 167.27 364.61 75.40
EBIT 97.38 97.87 34.77 5.65 2.91
Net Profit 64.37 70.69 29.18 3.19 -2.98
EPS 62.79 69.84 30.63 7.88 4.65
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -2,161.18-1,555.65-47.10-135.81-199.59
Net Margin info ---393.28-60.30----
Return on equity info 42.8162.44--41.1537.97
Return on Capital info -158.42-125.55---159.44-165.29
Return on Assets info -87.24-77.22-26.19-78.62-73.11
Debt to Equity (x) info -----1.16-1.31-1.18
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
--
-159.44
-165.29
-150.54
-72.65
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
--
41.15
37.97
49.31
45.29
Peer Median
17.28
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-26.19

Lower than Peers by 28.80

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
-26.19
-78.62
-73.11
-110.00
-58.83
Peer Median
2.61
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-47.10

Lower than Peers by 61.79

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
-47.10
-135.81
-199.59
-6,148.15
-520.57
Peer Median
14.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-60.30

Lower than Peers by 67.92

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
-60.30
-145.26
-241.44
-6,913.92
-259.21
Peer Median
7.61
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
0.00
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

167.27

Higher than Peers by 159.95

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
167.27
1.26
22.85
-0.88
0.11
Peer Median
7.32
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

34.77

Higher than Peers by 29.33

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
34.77
-53.96
22.56
-41.50
25.10
Peer Median
5.44
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

29.18

Higher than Peers by 23.76

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
29.18
-36.12
16.70
-33.67
14.46
Peer Median
5.42
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

30.63

Higher than Peers by 23.29

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
30.63
-0.31
0.23
-0.14
0.17
Peer Median
7.34
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

16.42

Higher than Peers by 12.32

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
16.42
--
--
--
--
Peer Median
4.10
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

-1.16

Lower than Peers by 1.65

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
-1.16
-1.31
-1.18
-1.28
-1.37
Peer Median
0.49
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

-0.33

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
-0.33
-0.01
0.00
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.09

Higher than Peers by 0.41

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
2.09
2.62
4.67
3.32
4.52
Peer Median
1.68
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.03

Higher than Peers by 0.80

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
2.03
2.52
4.67
3.20
4.21
Peer Median
1.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-3.33

Lower than Peers by 7.72

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
-3.33
-12.84
-4.46
-7.04
-5.03
Peer Median
4.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

39.67

Higher than Peers by 19.37

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
39.67
27.77
2.13
18.82
22.00
Peer Median
20.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.43

Higher than Peers by 0.04

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
0.43
0.54
0.30
0.02
0.09
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
--
52.44
5.33
369.65
86.62
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
--
172.81
784.23
4,075.31
-1,646.87
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
--
296.14
954.71
1,658.48
1,246.68
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
--
-70.89
-165.15
2,786.48
-2,806.93
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
--
-20.69
-9.70
-10.95
-2.37
Peer Median
43.90
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

123.68

Higher than Peers by 115.68

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
123.68
-7.27
-3.54
-5.20
-0.91
Peer Median
8.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-9.40

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
-9.40
-25.47
-14.30
-14.76
-6.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

14,600

Higher than Peers by 12,160

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
BridgeBio Pharma (BBIO)
14,600
--
--
--
--
Peer Median
2,440
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...

Mutual Fund Insight turns 24! 🎉 Get 2 FREE anniversary guides: The Right SIP + The Big Funds